PCOS Healthcare Trends · Evergreen explainer
PCOS and type 2 diabetes: the screening timeline nobody hands you
Most people diagnosed with PCOS, now also called PMOS for polyendocrine metabolic ovarian syndrome, leave the appointment knowing about cycles, skin, hair and fertility. Fewer leave with a date. Yet diabetes screening is the one part of this condition that comes with an explicit timetable in the 2023 International Evidence-based Guideline: a glucose check at diagnosis, a recheck every one to three years after that, a named test that is more accurate than the others, and extra checks around pregnancy. This piece lays that timeline out in plain language, explains why the choice of test matters more in this condition than in most, shows what the follow-up studies found about how glucose tolerance changes over time, and lists the questions that make sure the recheck actually happens.
Why diabetes belongs in this conversation from day one
The link is not a scare tactic, and it is not only about weight. The 2023 International Evidence-based Guideline states it as its first diabetes recommendation: healthcare professionals and women with PCOS should be aware that, regardless of age and BMI, women with PCOS have an increased risk of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes. The US Centers for Disease Control and Prevention puts a scale on it on its PCOS page: more than half of women with PCOS develop type 2 diabetes by age 40, in the CDC’s own summary. Our explainer on insulin resistance in PCOS/PMOS walks through the mechanism in plain steps: cells respond less to insulin, the pancreas compensates with more, and blood glucose creeps up over years, often silently.
How common abnormal results are at a first proper check surprised researchers early on. In a frequently cited 1999 study in Diabetes Care, 122 women with PCOS were given a standard oral glucose tolerance test: 45 percent had abnormal glucose tolerance at that single testing session, 35 percent in the impaired range and 10 percent in the diabetes range. That was a clinic sample, not a prediction for any one person, and diagnostic definitions have been refined since. What it established, and what later work has kept confirming, is that a normal fasting result at a routine visit is not the same thing as a completed glucose assessment in this condition. The rest of this piece is about what a completed assessment looks like, and when it should happen again.
The timeline, in one place
The guideline’s screening positions, translated into a calendar, are these:
- At diagnosis. Glycaemic status should be assessed at diagnosis in all adults and adolescents with PCOS. Not at some later annual physical, and not only when weight is high: at diagnosis, for everyone with the diagnosis. If you were diagnosed years ago and glucose was never checked, that first step is still outstanding, and asking for it is reasonable. Our explainer on how PCOS/PMOS is diagnosed shows where this check sits inside the full workup.
- Every 1 to 3 years after that. Glycaemic status should be reassessed every one to three years, based on additional individual risk factors for diabetes. The range is deliberate: one year for people with more risk layered on, up to three years for people with less. The next section covers what moves a person toward the one-year end.
- Around pregnancy. The guideline says an oral glucose tolerance test should be considered in all women with PCOS who do not already have diabetes when they are planning pregnancy or seeking fertility treatment. If it was not done before conception, it could be offered at the first prenatal visit, and all women with PCOS should be offered the test at 24 to 28 weeks of pregnancy. Our piece on PCOS and fertility covers the wider preconception picture.
US diabetes guidance points the same way. The American Diabetes Association’s Standards of Care screening table lists polycystic ovary syndrome by name as one of the risk factors that should prompt diabetes testing in adults with overweight or obesity, and it says people whose results fall in the prediabetes range should be tested yearly. The international guideline goes further for this condition in one respect: its at-diagnosis and 1-to-3-year positions apply regardless of BMI.
The three tests, and why the guideline ranks one first
Three blood tests are used to assess glucose status, and they do not see the same thing:
- The 75g oral glucose tolerance test (OGTT). You fast overnight, have a blood draw, drink a measured glucose drink, and have a second draw two hours later. It is the only one of the three that shows what your glucose does after a load, which is where the earliest abnormality in this condition usually appears. The guideline recommends it as the most accurate test to assess glycaemic status in PCOS, regardless of BMI.
- Fasting plasma glucose. A single draw after an overnight fast. Convenient, and it catches part of the picture, but by definition it cannot see a rise that only happens after eating or after a glucose load.
- HbA1c, also written A1C. A single draw that reflects average blood glucose over roughly the past three months. Our glossary defines HbA1c and the related terms in plain language. It needs no fasting, which is why it is so widely used, and that convenience is exactly the trade-off the guideline warns about.
The guideline’s wording on the fallbacks is specific: if an OGTT cannot be performed, fasting plasma glucose and/or HbA1c could be considered, noting significantly reduced accuracy. Significantly is doing real work in that sentence. In a systematic review of nine studies covering 2,628 women with PCOS, the review the guideline evidence base drew on for this question, HbA1c at the standard diabetes cutoff identified only about half of the diabetes cases the OGTT found (sensitivity 50 percent), and fasting glucose identified a little more (about 58 percent). The 1999 study above found the same pattern from the other direction: among the women with impaired glucose tolerance, the fasting glucose concentration was a poor predictor of the two-hour level. Read plainly: in this condition, a reassuring fasting glucose or A1C can sit on top of a two-hour result that is not reassuring, because the abnormality often lives in the post-load hours those tests never measure. That is a statement about test performance in study groups, not a prediction about your result. It is why, if you are offered only a fasting test or an A1C, asking whether an OGTT is appropriate for you is a fair and informed question.
What pushes a recheck toward one year
The guideline sets the 1-to-3-year range and says the exact interval depends on additional individual risk factors, without printing a scoring table. The factors clinicians commonly weigh when they choose the shorter end are the standard diabetes risk factors, and naming them helps you follow the reasoning at your own visit:
- A previous result in the prediabetes range. The ADA position is yearly testing for people with prediabetes-range results, and a prior impaired result is the clearest reason to sit at the one-year end.
- Family history. The guideline notes that first degree relatives of people with PCOS should also be aware of the increased diabetes risk. A parent or sibling with type 2 diabetes adds weight to a shorter interval.
- Change since the last test. Weight gain, a rising fasting glucose trend even inside the reference range, or a new pregnancy plan all shorten the sensible gap. Pregnancy planning brings its own testing window, described above.
- Background and age. Diabetes risk differs across ethnic groups and rises with age, and the guideline directs clinicians to weigh both when setting assessment frequency.
- A previous pregnancy with gestational diabetes. US guidance treats that history as a reason for lifelong testing at least every three years in the general population, and clinicians often place people with both that history and PCOS at the frequent end.
Follow-up studies show why the recheck exists at all: glucose tolerance in this condition moves. In a controlled study published in the Journal of Clinical Endocrinology and Metabolism in 2005, 71 women with PCOS and normal or near-normal starting results were retested after an average of about two and a half years; the shares with impaired glucose tolerance and with type 2 diabetes were both higher at follow-up than at baseline, and the authors concluded that periodic rescreening is warranted. Those are group averages from one clinic cohort, not a schedule for any individual. The individual schedule is the one you and your clinician set from your own results and risk factors, and then write down.
The words on the lab report, in plain language
- Normal glucose tolerance means both the fasting and, when an OGTT is done, the two-hour value sit in the reference range. It is a snapshot with a recheck date, not a lifetime pass.
- Impaired fasting glucose means the fasting value is above the reference range but below the diabetes threshold.
- Impaired glucose tolerance means the two-hour OGTT value is in that in-between range. It is only visible if the two-hour test is done, which is the practical reason the test choice matters.
- Prediabetes is the umbrella term US guidance uses for those in-between ranges. It is a risk category, not a diagnosis of diabetes, and it is the result that most often moves a recheck to yearly.
- Type 2 diabetes is diagnosed when a result meets the diabetes threshold, usually confirmed on repeat testing. A screening result starts that conversation; it does not finish it on its own.
What screening is not: the insulin test question
Patients frequently ask for an insulin level, reasoning that insulin resistance is the engine here, so measuring insulin should be the screening test. The guideline addresses this directly, and its answer is no: insulin resistance is a pathophysiological factor in PCOS, but clinically available insulin assays are of limited clinical relevance and are not recommended in routine care. There is no agreed standard for the assays and no cutoff that changes what happens next, so glucose status, measured with the tests above, is what screening follows. Our insulin resistance explainer covers this in more depth, including why the guideline recommends glucose testing instead of insulin testing at every BMI, lean presentations included. If weight is not part of your picture, our piece on lean PCOS explains why the same screening floor still applies to you.
Who owns the recheck date
- Primary care or an OB-GYN usually holds the screening calendar: ordering the test the guideline directs, recording the result category in words, and setting the next date from the 1-to-3-year range.
- An endocrinologist leads when results are in the prediabetes or diabetes range, when glucose questions sit alongside other hormone questions, or when the interval needs individual judgement because risk factors are layered.
- A registered dietitian is part of the team the guideline describes for the prevention strategies it tells clinicians and patients to prioritise. What any strategy involves for a given person is a decision for that care relationship. This page makes no claim about what any approach does.
The practical failure mode is rarely a refused test. It is a normal result filed with no next date attached, in a chart that changes doctors twice before three years pass. Leaving the visit with the recheck year written down, and knowing which clinician owns it, is the whole game. Our piece on which clinician does what maps the team in full, and our guide to questions to bring to a first appointment shows how to set this record up from the first visit.
What this does not mean
- A PCOS diagnosis is not a diabetes diagnosis. Many people with this condition never develop diabetes. The risk is raised, which is why screening exists; it is not a certainty, which is why screening is a timetable and not a verdict.
- A lean BMI does not remove the screening. The guideline’s at-diagnosis and recheck positions, and its OGTT recommendation, are stated regardless of BMI.
- One normal A1C does not close the question. The guideline records significantly reduced accuracy for HbA1c and fasting glucose in this population. A normal fallback result and a normal OGTT are not the same evidence.
- Feeling well does not settle it either way. The in-between glucose ranges usually have no symptoms, which is the reason a scheduled test, rather than how you feel, carries the monitoring.
- This page names no treatment and no prevention result. It gives no doses, recommends no medicine, diet or programme, and describes no outcome you should expect. It reports what the guideline recommends for testing, and what studies measured about the tests.
Questions to bring to an appointment about diabetes screening
- Was my glucose status assessed when I was diagnosed, and if so, with which test, and what was the result category in words?
- Given the guideline names the 75g OGTT as the most accurate test in PCOS, is that the test I should have, and if we use fasting glucose or A1C instead, how do we read a normal result given the reduced accuracy?
- When is my next recheck, one, two or three years, and which of my risk factors set that interval?
- Can the recheck date and the owning clinician be written in my record and my visit summary, so it survives a change of doctor?
- If I am planning pregnancy, when should the preconception OGTT happen, and what is the plan for the first prenatal visit and for 24 to 28 weeks?
- If a result lands in the prediabetes range, what changes: how often am I retested, and who coordinates that follow-up?
- Should my parents or siblings know that first degree relatives are part of this risk picture too?
What this means when you are finding care
The clinician you want can tell you which glucose test you had, name your result category, and state your recheck year without checking twice. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state, for example the Florida listings page, and skim the plain-language glossary before a visit.
Sources
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology and Metabolism, 2023, section 1.9 on impaired glucose tolerance and type 2 diabetes risk (increased risk regardless of age and BMI, glycaemic status assessed at diagnosis in all adults and adolescents, reassessment every 1 to 3 years, the 75g OGTT as the most accurate test regardless of BMI, fasting glucose and HbA1c as fallbacks with significantly reduced accuracy, OGTT around pregnancy planning, first prenatal visit and 24 to 28 weeks, and insulin assays not recommended in routine care) — read the guideline (PMC)
- Centers for Disease Control and Prevention, Diabetes and Polycystic Ovary Syndrome (PCOS) page, including its statement that more than half of women with PCOS develop type 2 diabetes by age 40 and its summary of insulin resistance in this condition — read the CDC page
- Ehrmann DA, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome, Diabetes Care, 1999 (122 women given a standard OGTT; 45 percent with abnormal glucose tolerance, 35 percent impaired and 10 percent in the diabetes range; fasting glucose a poor predictor of the two-hour level in the impaired group) — read the abstract (PubMed)
- Legro RS, et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study, Journal of Clinical Endocrinology and Metabolism, 2005 (71 women with PCOS retested after an average of about 2.5 years; impaired glucose tolerance and diabetes shares higher at follow-up; authors supported periodic rescreening) — read the abstract (PubMed)
- American Diabetes Association, Standards of Care screening criteria table, which lists polycystic ovary syndrome as a risk factor prompting diabetes testing and yearly testing for people with prediabetes-range results — read the ADA criteria table
- The guideline programme home at Monash University — Monash Centre for Health Research and Implementation, PCOS
- Federal overview of the condition — NICHD, PCOS topic page
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.